Genprex Inc. Discusses Plans to Expand Clinical Trials in Fight Against Cancer in Exclusive Audio Interview with NetworkNewsW...
March 19 2019 - 8:30AM
via NetworkWire – NetworkNewsAudio (NNA), a NetworkNewsWire
(NNW) Solution that delivers clients unparalleled visibility,
recognition and brand awareness in the investment community,
today announces the online availability of its interview
with Genprex Inc., a clinical stage gene therapy company
developing a new approach to treating cancer.
NNW’s Stuart Smith introduces Genprex CEO and
Chairman Rodney Varner, JD, for a compelling discussion on the
company’s initial product candidate, Oncoprex(TM), an immunogene
therapy for non-small cell lung cancer (NSCLC).
The interview can be heard
at http://nnw.fm/QUUu0
The American Cancer Society reports that NSCLC is the most
common type of lung cancer, accounting for about 85 percent of all
lung cancer. More people die of the disease each year than of
colon, breast and prostate cancers combined. Survival for
late-stage lung cancer has not improved significantly in the past
25 years, despite radical advances in drug development and novel
therapeutic standards. Genprex technologies are being developed to
overcome genomic limitations, which are inherent in targeted
therapies, to provide new treatment solutions to large cancer
populations and improve outcomes.
“Our approach is to deliver a tumor suppressor
gene to tumor cells by encapsulating the gene in a
DOTAP:cholesterol nanoparticle which is then injected
intravenously and targets tumor cells,” Varner explains. “Our
technology is currently in a phase II clinical trial for non-small
cell lung cancer being conducted at the M.D. Anderson Cancer Center
(University of Texas) in Houston.”
Oncoprex has a multimodal mechanism of action whereby it
interrupts cell signaling pathways that cause replication and
proliferation of cancer cells, re-establishes pathways for
apoptosis (or programmed cell death) in cancer cells, and modulates
the immune response against cancer cells. Oncoprex has also been
shown to block mechanisms that create drug resistance. Preclinical
and clinical data indicate that Oncoprex may be effective alone or
in combination with targeted small molecule therapies and
immunotherapies.
Varner says he is enthusiastic about the
important work being accomplished at Genprex, which was formed in
2009. The company continues to add industry-leading members to its
board of directors and scientific advisory board which includes
Nobel Prize laureate Dr. James E. Rothman, PhD, who serves as a
strategic advisor.
“I’m very proud of our board and scientific
advisors,” Varner says. “I think it would be hard to find a more
distinguished group.”
Genprex plans to continue its current phase II clinical trial at
the Texas cancer center and expects to advance additional clinical
trials at other sites. The company’s long-term goal is to continue
to develop its immunogene therapies and add additional products to
its drug pipeline that attack not only lung cancer but many other
cancers, Varner concludes.
About Genprex Inc.
Genprex Inc. is a clinical-stage gene therapy company developing
potentially life-changing technologies for cancer patients, based
upon a unique proprietary technology platform, including Genprex’s
initial product candidate, Oncoprex(TM) immunogene therapy for
non-small cell lung cancer (NSCLC). Genprex’s platform technologies
are designed to administer cancer fighting genes by encapsulating
them into nanoscale hollow spheres called nanovesicles, which are
then administered intravenously and taken up by tumor cells where
they express proteins that are missing or found in low quantities.
Oncoprex has a multimodal mechanism of action whereby it interrupts
cell signaling pathways that cause replication and proliferation of
cancer cells, re-establishes pathways for apoptosis, or programmed
cell death, in cancer cells, and modulates the immune response
against cancer cells. Oncoprex has also been shown to block
mechanisms that create drug resistance.
Visit the company’s web site at www.genprex.com or
follow Genprex on Twitter at twitter.com/genprex, Facebook
at facebook.com/genprexinc, and LinkedIn
at linkedin.com/company/genprex.
About
NetworkNewsAudio
NetworkNewsAudio (NNA), a NetworkNewsWire
(NNW) Solution, allows you to sit back and listen to market
updates, CEO interviews and a Company AudioPressRelease (APR).
These audio clips provide snapshots of position, opportunity and
momentum. NetworkNewsAudio (NNA) can assist your company
by cutting through the overload of information in today's market,
NNA brings its clients unparalleled visibility, recognition and
brand awareness. NetworkNewsWire (NNW) is where news,
content and information converge. NetworkNewsWire
(NNW) is a comprehensive provider of news aggregation and
syndication, enhanced press release services and a full array of
social communication solutions. As a multifaceted financial news
and distribution company with an extensive team of journalists and
writers, NNW has the unparalleled ability to reach a wide audience
of investors, consumers, journalists and the general public with an
ever-growing distribution network of more than 5,000 key
syndication outlets across the nation. For more information,
visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on
the NetworkNewsWire website applicable to all content provided by
NNW, wherever published or
re-published: http://NNW.fm/Disclaimer.
Cautionary Note Regarding
Forward-Looking Statements
Statements contained in this press release
regarding matters that are not historical facts are
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Such statements include, but are not limited to,
statements regarding the effects of Oncoprex on cancer. Risks and
uncertainties associated with Genprex and its lead product
candidate Oncoprex are described more fully under the caption "Risk
Factors" and elsewhere in our filings and reports with the United
States Securities and Exchange Commission. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. We undertake no obligation to update
such statements to reflect events that occur or circumstances that
exist after the date on which they were made.
Investor RelationsGNPX investor relations(877)
774-GNPX (4679) ext. #2investors@genprex.com
Media ContactGenprex Media Relations(877)
774-GNPX (4679) ext. #3media@genprex.com
Corporate Communications:NetworkWire (NW)New
York, New Yorkwww.NetworkNewsWire.com212.418.1217
OfficeEditor@NetworkWire.com
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Genprex (NASDAQ:GNPX)
Historical Stock Chart
From Apr 2023 to Apr 2024